Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05275166
Other study ID # 35RC21_9740_CRAVING-NET
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 2023
Est. completion date November 2025

Study information

Verified date November 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol is the most consumed psychoactive substance in France and is responsible for 49,000 deaths per year in the country. Addictions, characterized by "the repeated impossibility of controlling a behavior and the continuation of this behavior despite the knowledge of its negative consequences", are a major public health issue in France and worldwide. Alcohol dependence (DSM-5 moderate to severe use disorder) is a chronic behavioral disorder, whose main characteristic is its high and prolonged risk of "relapse", i.e. the resumption of problematic consumption after a period of improvement (abstinence or reduction). One of the main components of addiction is "craving", which can be defined as the irrepressible desire to use a substance (DSM-5, American Psychiatric Association). To date, despite functional imaging studies (fMRI), the brain mechanisms involved in craving remain poorly understood. In recent years, a new neuroimaging device has become available, both in research and in clinical settings: high-resolution electroencephalography (HRE). This non-invasive method allows to observe brain activity at the millisecond level. The objective of the CRAVING-NET project is to better understand brain function in alcohol addiction, and in particular in craving.


Description:

The objective of the CRAVING-NET project is to better understand brain function in alcohol addiction, and in particular in craving, using high-resolution electroencephalography. Brain activity following the induction of alcohol craving, as well as responses to questionnaires related to their relationship to alcohol and their state of health, which will be obtained in patients will be compared to the same responses in healthy volunteers.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2025
Est. primary completion date May 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: Patients (N=20): - Subject with moderate to severe DSM-5 alcohol use disorder hospitalized for withdrawal as part of their routine care. - Presence of spontaneous and/or in response to environmental stimuli (induced) self-described episodes of craving. - Males with age = 30 years and = 60 years; - Normal or corrected-to-normal visual acuity (declarative); - Right-handed; Healthy control volunteers (N=40): - Men with age = 30 years and = 60 years; - Normal or corrected-to-normal visual acuity; - Right-handed; - Smoker (current user, N=20) or Nonsmoker (never smoked, N=20); - Alcohol consumption below the low-risk drinking threshold (<10 standard drinks per week) Exclusion Criteria: For all subjects: - Alcohol use in the 24 hours prior to the experiment; - Consumption of psychoactive substances other than tobacco and alcohol (positive urine test). - Presence of a contraindication related to the MRI technique - Being under legal protection, and/or deprived of freedom; - Not mastering the French language (written and oral); - Inability to understand the information given on the study and/or to carry out the experimental task. For patients: - Presence of cognitive impairment (MoCA score < 25) - Absence of spontaneous or induced craving episodes - Decompensated cirrhosis: ascites and/or encephalopathy and/or jaundice and/or recent hemorrhage For healthy control volunteers: - Significant medical or surgical history related to the central nervous system; - Current use (< 30 days) of drugs affecting the central nervous system belonging to the class of antidepressants, sleeping pills and/or anxiolytics.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Induction of alcohol craving
Presentation of images that may induce craving for alcohol. Recording of brain activity
Other:
Questionnaires
Questionnaires related to alcohol, quality of life, anxiety and depression

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Source connectivity within large-scale brain networks Difference in source connectivity within large-scale brain networks following the induction of craving episodes between alcohol-dependent patients and matched healthy participants (smokers and non-smokers). Source connectivity is measured by the strength of connections between brain regions (ratio value between 0 (no communication) and 1 (strong communication)). 1 day
Secondary Variation in source connectivity based on AUQ Significant difference in source connectivity between patients and volunteers based on Alcohol Urge Questionnaire (AUQ,easures craving in patients with alcohol dependence; Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by averaging the item scores. Higher scores reflect greater craving. 1 day
Secondary Variation in source connectivity based on OCDS Significant difference in source connectivity between patients and volunteers based on Obsessive Compulsive Drinking Scale (OCDS , allows to obtain a global alcohol appetite score and to evaluate the craving, in 14 items with a compulsion sub-score and an obsessional sub-score. Higher scores reflect greater craving. 1 day
Secondary Variation in source connectivity based on psychological state Significant difference in source connectivity between patients and volunteers based on Hospital Anxiety and Depression scale (HAD , allows to obtain a anxiety score and a depression score to evaluate psychological state. Two subscores, one for anxiety and one for depression. Higher sub-scores reflect higher anxiety or depression. 1 day
Secondary Correlation between brain networks estimated by HRE and AUQ and OCDS scores Correlation between brain networks estimated by EEG-HR and AUQ and OCDS scores at 6 months only in patients 6 months
Secondary Correlation between EEG-HR and fMRI networks at inclusion Correlation between EEG-HR and fMRI networks at inclusion in patients and healthy volunteers 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Recruiting NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4